Chassagnon, Guillaume http://orcid.org/0000-0003-1487-7922
Martin, Clémence
Burgel, Pierre-Régis
Hubert, Dominique
Fajac, Isabelle
Paragios, Nikos
Zacharaki, Evangelia I.
Legmann, Paul
Coste, Joel
Revel, Marie-Pierre
Funding for this research was provided by:
Association Vaincre la Mucoviscidose
Article History
Received: 8 September 2017
Revised: 16 April 2018
Accepted: 26 April 2018
First Online: 4 June 2018
Compliance with ethical standards
:
: The scientific guarantor of this publication is Marie-Pierre Revel
: The authors of this manuscript declare relationships with the following companies:• Pierre-Régis Burgel, Dominique Hubert and Isabelle Fajac have received personal fees from Vertex Pharmaceuticals, outside the submitted work.• Guillaume Chassagnon and Marie-Pierre Revel have made a patent application for the image analysis method presented in this article.The other authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
: Joel Coste has significant statistical expertise.
: The need for informed consent was waived, in accordance with French rules for retrospective studies
: The study was approved by the Paris Ile de France I ethics committee (ref 13.652).
: The 17 study subjects of the development cohort have been previously reported in Chassagnon et al. [CitationRef removed].
: • retrospective• observational• multicentre study